Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Retained Earnings (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Retained Earnings for 6 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 106.37% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Dec 2025, up 106.37%, and an annual FY2025 reading of $2.2 million, up 106.37% over the prior year.
  • Retained Earnings was $2.2 million for Q4 2025 at Cytek Biosciences, up from -$57.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $2.2 million in Q4 2025 and bottomed at -$57.7 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$20.5 million, with a median of -$19.8 million recorded in 2021.
  • The sharpest move saw Retained Earnings soared 1280.0% in 2021, then tumbled 26661.03% in 2025.
  • Year by year, Retained Earnings stood at $897000.0 in 2021, then plummeted by 177.7% to -$697000.0 in 2022, then plummeted by 4086.23% to -$29.2 million in 2023, then dropped by 20.64% to -$35.2 million in 2024, then surged by 106.37% to $2.2 million in 2025.
  • Business Quant data shows Retained Earnings for CTKB at $2.2 million in Q4 2025, -$57.7 million in Q3 2025, and -$52.2 million in Q2 2025.